Presentation is loading. Please wait.

Presentation is loading. Please wait.

Pulmonary Function Tests Ghassan Jamaleddine, M.D. American University of Beirut.

Similar presentations


Presentation on theme: "Pulmonary Function Tests Ghassan Jamaleddine, M.D. American University of Beirut."— Presentation transcript:

1 Pulmonary Function Tests Ghassan Jamaleddine, M.D. American University of Beirut

2 Use of PFTs Evaluating breathlessness Initial evaluation of patient with known respiratory disease Following the course of a respiratory disease Pre-operative assessment Disability evaluation Screening of subclinical disease

3 Disadvantages of PFTs Patients cooperation and an informed technician are required Measures the lung and chest as a unit Evaluates disease at only one point in time Errors in programs of computer driven automated equipment

4 Routine PFTs Spirometry with or without Flow Volume loop Static lung volumes Single Breath Diffusing Capacity

5

6

7

8

9 Spirometry Forced vital capacity Forced Expiratory Volume in one second (FEV1) Percent Expired (FEV1/FVC or FEV1%) Forced Mid-Expiratory Flow (FEF 25-75) or Maximal Mid-Expiratory Flow (MMEF or MMF) Peak or Maximal Expiratory Flow Rate (PEF or MEFR)

10

11

12 Pattern of defects seen on PFTs Obstructive Vent defect –FVC reduced or Normal –FEV1 reduced –FEV1/FVC is reduced Example: Asthma, COPD Restrictive Vent defect –FVC reduced –FEV1 normal or reduced –FEV1/FVC is increased Example: pulmonary fibrosis, pleural effusion, neuromuscular

13

14

15

16 P 1 V1 = P2 (V1-Δ V)

17

18 Lung Volumes Functional Residual Capacity Expiratory Reserve Volume Residual Volume Inspiratory Capacity Total Lung Capacity Vital Capacity

19 FLOW VOLUME LOOP

20

21

22 Diffusion Transfer of a gas across a tissue sheet, governed by Ficks law Rate of Transfer = A D x P/T

23

24 Diffusion Capacity (measurement) A D x (P1- P2) T AD/T = Diffusion constante Rate of transfer (CO) = Vco = Dlco x (P1- P2) Dlco = Vco/ PA –Pa = Vco/ PA 25 ml/min/mmHg

25 Diffusing Capacity Influenced by: – Changes in alveolar-capillary membrane – Pulmonary circulation – Ventilation perfusion matching – Hemoglobin concentration

26 Diffusion Capacity Very important in –Interstitial lung disease –Drug induced lung injury Reduced in Emphysema because of destruction of alveolar units

27 PFT Patterns in Disease PFT results are best interpreted with knowledge of the patients history, physical exam and occasionally chest X-ray.

28 PFTDisease ObstructiveRestrictive FVC N or FEV1 FEV1/FVC N MMEF or V50 N or MVV N or FRC N or RV TLC N or

29 Case 1 14 year old boy came to ER with increasing shortness of breath History of asthma since age of 2-3 Maintained on ICS and Beta2 agonists Followed by Family physician, past year frequent attacks, several courses of antibiotics and systemic corticosteroids

30 Case 1 (contd) In ER started on iv steroids and inhaled Beta 2 agonists, no improvement, admitted No history of atopy, no nasal nor GI symptoms, no family history of asthma Exam: decrease breath sounds Admitted

31 Case 1 (contd) CXR, CBC, chemistry non revealing After 2 days of treatment with steroids and inhaled bronchodilators there was no improvement in symptoms Noticed faint voice and tachypnea on minimal exercise PFT obtained

32 Case PFTs FVC 93%, FEV1 45%, FEV1/FVC 41% TLC 90%, RV 90%, DLCO 100% ?????

33

34 Case 1(contd) FOB: subglottic stenosis (? Congenital) Tracheostomy followed by reconstructive surgery Total recovery, no more asthma treatment

35 Case 2 32 year old man presented with 2 months history of increasing shortness of breath Married, non-smoker, bank employee, no history of asthma No other symptoms Shortness of breath increasing before presentation Seen by multiple physicians, given a number of antibiotics, bronchodilators, aminophylline

36 Case 2 (Contd) Exam: BP 120/80, RR 18, P100, BMI 29, afebrile, chest: clear… rest of exam was normal ER: ABGs normal, CXR: normal, CT angio: normal, neuro consult (fellow): no neuro problem Patient reassured by the team

37 Case 2 (contd) Spirometry obtained: –FVC 50% –FEV1 55% –FEV1/FVC 80% –MVV 20% –????

38 Case 2 (contd) Neurology attending reconsulted EMG: Myasthenia Gravis Diagnosis suspected from FVC and MVV –Neuromuscular illness

39 Case 3 A 60 year old man with history of ex- smoking, history of seasonal colds, admitted for hernia operation Pulmonary consulted for pre-op clearance because of obesity The patient denied pulmonary complaints, but his wife disclosed that he has a chronic cough

40 Predicted Values Measured Values % Predicted FVC6.00 liters4.00 liters67 % FEV15.00 liters2.00 liters40 % FEV1/FVC83 %50 %60 % Case 3 Obstructed defect

41 Case 3

42 Pre-operative screening Patients with known pulmonary illness or symptoms Overweight patients Patients undergoing surgery in the chest or near the diaphragm

43 Case 4 A 65 year old man non-smoker, lawyer, admitted for elective Lap Chole. Reports long history of mild cough, and dyspnea on exertion Physical exam: bibasilar dry crackles (velcrow), clubbing of the fingers

44 Case 4 Predicted ValuesMeasured Values% Predicted FVC5.68 liters4.43 liters65 % FEV14.90 liters3.52 liters60 % FEV1/FVC84 %79 %94 % Restricted defect

45 Case 4 TLC 60% RV 40% DLCO 40% HRCT

46 Case 4

47 Case 5 68 year old man with progressive dyspnea of one year duration, ex-smoker, no cough, no wheezing, no orthopnea… History of CAD, SVT post angioplasty on multiple medication EF% 55 Meds: Plavix, beta one blocker, diuretics, cordarone, ARB,

48 Case 5 FVC 50% FEV1 55% FEV1/FVC 85% TLC 70% DLCO 50%

49 Case 5 PFTs: Major drop in FVC and DLCO compared to the PFT done 2 years earlier HRCT of chest: Increased markings over the bases, with areas of increased enhancement…. Consistent with Amiodarone toxicity

50 Follow up patients Connective Tissue diseases (e.g. scleroderma) Patients on Therapy that might affect the pulmonary system Neuromuscular diseases

51 Follow up Patients with Lung Diseases Obstructive airway diseases Interstitial lung diseases –Sarcoidosis –IPF –ILD (CTD)

52 Conclusion PFTs –Spirometry –Lung volumes –DLCO

53 Conclusion: Indications Evaluating breathlessness Initial evaluation of patient with known respiratory disease Following the course of a respiratory disease Pre-operative assessment Disability evaluation Screening of subclinical disease


Download ppt "Pulmonary Function Tests Ghassan Jamaleddine, M.D. American University of Beirut."

Similar presentations


Ads by Google